American Conference Institute (ACI) a conference on Patent Reform for Life Sciences Companies from January 31 to February 1, 2012 in New York, NY. Topics of discussion at the conference will include:
• Scrutinizing the specific provisions of patent reform in The America Invents Act (S. 23 & H.R. 1249);
• Analyzing the impact of a change to the first to file system from a first to invent system;
• Strategic tools for taking advantage of or defending against expanded opposition procedures including inter partes reviews, supplemental examinations, post-grant reviews and multiple oppositions;
• Accounting for changes to PTO fees including the reduction of fees for small and micro-entities;
• Determining what constitutes prior art under the new requirements;
• Navigating changes to PTO practices and procedures; and
• Revamping strategic IP planning in light of new requirements under patent reform.
In particular, ACI's faculty will offer presentations on the following topics:
• Keynote address: USPTO Commissioner Robert L. Stoll;
• The timeline of enactment: Identifying what needs to be done now and planning for future changes;
• First to file: Developing an updated and comprehensive intellectual property strategy in the new race to the Patent Office regime;
• Audience Q&A open forum for discussion on the impact of first to file;
• Examining the consequences of changes to inventorship provisions;
• Prior art and public disclosure: Identifying what constitutes prior art under the revised §102;
• Expediting the examination process by strategically using the different examination tracks, including the new prioritized examination option;
• Balancing the seemingly contradictory best mode provisions to maximize IP protection;
• Preparing for emerging patent challenges under the new post grant review system;
• Accounting for changing evidentiary requirements and procedures for inter partes review;
• Examining the potential ramifications of patent reform on Hatch Waxman litigation and the brand/generic wars;
• Audience Q&A open forum for discussion on the new litigation provisions and the impact on life sciences companies;
• Specific considerations for universities, non-profit institutions and micro-entities; and
• Analyzing the potential impact of the "miscellaneous provisions" on life sciences companies.
In addition, a pre-conference workshop entitled "Patent Reform 101: Overview of the Fundamental Provisions in the America Invents Act" will be offered from 1:00 to 4:00 pm on January 30, 2012.
A program for this conference, including an agenda and detailed descriptions of conference sessions can be obtained here. The registration fee for the conference is $2,195. Patent Docs readers who reference the discount code "PD 200" will receive $200 off the current price tier when registering. Those interested in registering for the conference can do so here, by calling 1-888-224-2480, or by faxing a registration form to 1-877-927-1563.
Patent Docs is a media partner of the Patent Reform for Life Sciences Companies conference.
"patent reform"
“This is not a patent reform bill” Senator Maria Cantwell (D-WA) complained, despite other democrats praising the overhaul. “This is a big corporation patent giveaway that tramples on the right of small inventors.”
Senator Cantwell is right. Just because they call it “reform” doesn’t mean it is. The agents of banks, huge multinationals, and China are at it again trying to brain wash and bankrupt America.
They should have called the bill the America STOPS Inventing Act or ASIA, because that’s where it is sending all our jobs.
The patent bill is nothing less than another monumental federal giveaway for banks, huge multinationals, and China and an off shoring job killing nightmare for America. Even the leading patent expert in China has stated the bill will help them steal our inventions. Who are the supporters of this bill working for??
Patent reform is a fraud on America. This bill will not do what they claim it will. What it will do is help large multinational corporations maintain their monopolies by robbing and killing their small entity and startup competitors (so it will do exactly what the large multinationals paid for) and with them the jobs they would have created. The bill will make it harder and more expensive for small firms to get and enforce their patents. Without patents we cant get funded. Yet small entities create the lion's share of new jobs. According to recent studies by the Kauffman Foundation and economists at the U.S. Census Bureau, “startups aren’t everything when it comes to job growth. They’re the only thing.” This bill is a wholesale slaughter of US jobs. Those wishing to help fight this bill should contact us as below.
Small entities and inventors have been given far too little voice on this bill when one considers that they rely far more heavily on the patent system than do large firms who can control their markets by their size alone. The smaller the firm, the more they rely on patents -especially startups and individual inventors. Congress tinkering with patent law while gagging inventors is like a surgeon operating before examining the patient.
Those wishing to help fight big business giveaways should contact us as below and join the fight as we are building a network of inventors and other stakeholders to lobby Congress to restore property rights for all patent owners -large and small.
Please see http://truereform.piausa.org/default.html for a different/opposing view on patent reform.
http://docs.piausa.org/
Posted by: staff | November 27, 2011 at 11:43 AM